Thromboembolic Events after COVID-19 Vaccination: An Italian Retrospective Real-World Safety Study.

Francesca Futura BernardiAnnamaria MascoloMarina SarnoNicolina CapoluongoUgo TramaRosanna RuggieroLiberata SportielloGiovanni Maria FuscoMassimo BisognoEnrico CoscioniAnna IervolinoPierpaolo Di MiccoAnnalisa CapuanoAlessandro Perrella

Published in: Vaccines (2023)

We observed a higher reporting of thromboembolic events with viral-vector-based vaccines (Oxford-AstraZeneca and Janssen) and an increased likelihood of being exposed to the Oxford-AstraZeneca vaccine compared to the mRNA vaccines (Pfizer-BioNtech and Moderna) among thromboembolic cases.

Keyphrases

sars cov
atrial fibrillation
coronavirus disease
cross sectional